In this article, the epidemiology of eosinophilic esophagitis (EoE) is reviewed. Demographic features and natural history are described, the prevalence and incidence of EoE are highlighted, and risk factors for…
Eosinophilic esophagitis (EoE) is increasing in western nations. Symptoms in infants and young children include feeding difficulties, failure to thrive, and gastroesophageal reflux. School-aged children may present with vomiting, abdominal…
Initial case series describing children and adults with symptoms related to esophageal dysfunction and dense esophageal eosinophilia lead to recognition of a “new” disease, eosinophilic esophagitis (EoE). Clinical, basic, and…
Ikuo Hirano, MD, Editor Eosinophilic esophagitis (EoE) has emerged over the past two decades as an important cause of upper gastrointestinal symptoms in both adults and children. Defined as a…
Forthcoming Issues September 2014 Biologics of IBD Edward Loftus, Editor December 2014 Upper GI Bleeding Ian Gralnek, Editor March 2015 Gastroparesis Henry P. Parkman, Editor Recent Issues March 2014 Gastroesophageal…
Gary W. Falk, MD, MS, Editor Eosinophilic esophagitis (EoE) is a disease that was virtually unheard of 20 years ago. Yet, in recent years, there has been an explosive increase…
Despite the success of antitumor necrosis factor (TNF) therapy in Crohn’s disease, there remains a need for biologic therapy that targets other immune pathways of disease. Ustekinumab is a fully…
Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target…
Lymphocyte homing antagonists represent promising therapeutic agents for the treatment of idiopathic inflammatory bowel disease (IBD). Several critical molecules involved in the recruitment of inflammatory cells in the intestine, including…
Biologic therapies, including the anti–tumor necrosis factor-α and cell adhesion molecule inhibitor drugs, have revolutionized the treatment of moderate-to-severe inflammatory bowel disease. Since the introduction of anti–tumor necrosis factor therapies,…
